Annual report pursuant to Section 13 and 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY

v3.24.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY - USD ($)
$ in Thousands
Common stock
Additional paid in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Total
Balance at the beginning of the period, shares at Dec. 31, 2020 928,754,958        
Balance at the beginning of the period at Dec. 31, 2020 $ 1,325 $ 935,706 $ (10,048) $ (585,756) $ 341,227
Increase (Decrease) in Stockholders' Equity          
Issuance of shares upon exercise of stock options $ 8 751     $ 759
Issuance of shares upon exercise of stock options (in shares) 5,723,646       5,723,646
Issue of shares under At The Market sales agreement, net of commission and expenses $ 4 2,525     $ 2,529
Issue of shares under At The Market sales agreement, net of commission and expenses (in shares) 3,069,330        
Other comprehensive loss (gain)     (1,094)   (1,094)
Share-based compensation expense   20,629     20,629
Net loss       (158,090) (158,090)
Balance at the end of the period at Dec. 31, 2021 $ 1,337 959,611 (11,142) (743,846) 205,960
Balance at the end of the period, shares at Dec. 31, 2021 937,547,934        
Increase (Decrease) in Stockholders' Equity          
Issuance of shares upon exercise of stock options $ 8 42     $ 50
Issuance of shares upon exercise of stock options (in shares) 5,823,534       5,823,534
Issue of shares under At The Market sales agreement, net of commission and expenses $ 54 12,763     $ 12,817
Issue of shares under At The Market sales agreement, net of commission and expenses (in shares) 43,738,422        
Other comprehensive loss (gain)     10,267   10,267
Share-based compensation expense   18,240     18,240
Net loss       (165,456) (165,456)
Balance at the end of the period at Dec. 31, 2022 $ 1,399 990,656 (875) (909,302) $ 81,878
Balance at the end of the period, shares at Dec. 31, 2022 987,109,890       987,109,890
Increase (Decrease) in Stockholders' Equity          
Issuance of shares upon exercise of stock options $ 18 238     $ 256
Issuance of shares upon exercise of stock options (in shares) 14,614,410       14,614,410
Issue of shares under At The Market sales agreement, net of commission and expenses $ 5 619     $ 624
Issue of shares under At The Market sales agreement, net of commission and expenses (in shares) 3,854,496        
Issuance of shares upon acquisition of TCR2 $ 443 60,320     60,763
Issuance of shares upon acquisition of TCR2 (in shares) 357,429,306        
Other comprehensive loss (gain)     (2,873)   (2,873)
Share-based compensation expense   12,736     12,736
Net loss       (113,871) (113,871)
Balance at the end of the period at Dec. 31, 2023 $ 1,865 $ 1,064,569 $ (3,748) $ (1,023,173) $ 39,513
Balance at the end of the period, shares at Dec. 31, 2023 1,363,008,102       1,363,008,102